Does Empagliflozin Linagliptin Metformin Hydrochloride Interact with Zonisamide?
Empagliflozin Linagliptin Metformin Hydrochloride and Zonisamide have a major drug interaction according to U.S. FDA drug labeling data. Zonisamide causes decreased serum bicarbonate and metabolic acidosis; concomitant use with TRIJARDY XR may increase risk of lactic acidosis. The mechanism involves carbonic anhydrase inhibition leading to metabolic acidosis. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Empagliflozin Linagliptin Metformin Hydrochloride Class
- Dipeptidyl Peptidase 4 Inhibitor
- Zonisamide Class
- Anti-epileptic Agent
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Empagliflozin Linagliptin Metformin Hydrochloride and Zonisamide occurs because carbonic anhydrase inhibition leading to metabolic acidosis. Clinically, this means zonisamide causes decreased serum bicarbonate and metabolic acidosis; concomitant use with trijardy xr may increase risk of lactic acidosis. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Empagliflozin Linagliptin Metformin Hydrochloride and your doctor is considering prescribing Zonisamide (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider